Do upper and lower camptocormias affect gait and postural control in patients with Parkinson&apos;s disease? An observational cross-sectional study by Geroin, Christian et al.
Research Article
Do Upper and Lower Camptocormias Affect Gait and Postural
Control in Patients with Parkinson’s Disease? An Observational
Cross-Sectional Study
Christian Geroin ,1,2 Marialuisa Gandolﬁ ,2,3 Isacco Maddalena,3 Nicola Smania ,2,3
and Michele Tinazzi 1,2
1Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences,
University of Verona, Verona, Italy
2Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
3Neuromotor and Cognitive Rehabilitation Research Center (CRRNC), Department of Neurological and Movement Sciences,
University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy
Correspondence should be addressed to Marialuisa Gandolﬁ; marialuisa.gandolﬁ@univr.it
Received 19 April 2019; Accepted 8 July 2019; Published 24 July 2019
Guest Editor: Mayela Rodriguez-Violante
Copyright © 2019 Christian Geroin et al. )is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Gait impairments and camptocormia (CC) are common and debilitating in patients with Parkinson’s disease (PD). Two types of
CC aﬀect patients with PD, but no studies investigated their relative contribution in worsening gait and postural control.
)erefore, we investigated spatiotemporal gait parameters, gait variability, and asymmetry and postural control in PD patients
(Hoehn & Yahr ≤4) with upper CC and lower CC and patients without CC. )is observational cross-sectional study involving
patients with PD and upper CC (n � 16) and lower CC (n � 14) and without CC (n � 16). )e primary outcome measure was gait
speed assessed by the GAITRite System. )e secondary outcome measures were other spatiotemporal parameters, gait variability,
and asymmetry. Postural control and balance were assessed with posturography and the Mini-BESTest. Patients with lower CC
showed a higher H&Y stage (p � 0.003), a worse PDQ8 (p � 0.042), and a lower Mini-BESTest score (p � 0.006) than patients
with PD without CC. Patients with lower CC showed a reduced gait speed (p � 0.012), stride length, and velocity than patients
with PD without CC. Upper CC patients showed a higher stride length than lower CC ones (p � 0.007). In the eyes open and
closed condition, patients with lower CC showed a higher (worse) velocity of CoP displacement in mediolateral direction and
length of CoP than patients with PD without CC. No signiﬁcant between-group diﬀerences were measured in gait variability and
asymmetry. In conclusion, lower CC was associated with more severe gait and postural control impairment than patients with
upper CC and without CC. Categorizing CC based on the bending fulcrum is compulsory to identify patients with the worst
performance and to implement speciﬁc rehabilitation programs.
1. Introduction
Gait impairments and camptocormia (CC) are common and
debilitating in patients with Parkinson’s disease (PD) [1–6].
)ey impose substantial disability on these patients, in-
creasing the risk of falling, and related injuries, and reducing
the quality of life [1–6]. According to a recent conceptual
model, gait disturbances can be characterized using a
principal component analysis in ﬁve independent domains:
pace, rhythm, variability, asymmetry, and postural control
domains [7]. In PD, the three principal gait impairments
(gait slowness, increased variability, and postural control
deﬁcits) fall into these domains [5].
In the current literature, the inﬂuence of postural ab-
normalities on gait disturbances has been rarely explored.
On the one hand, it depends on the fact that a consensus of
diagnostic criteria on postural abnormalities in PD has been
only recently reached. Pisa syndrome was deﬁned as at least
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10° lateral ﬂexion of the trunk, which typically resolves by
passive mobilisation or supine positioning [3]. Antecollis
relates to forward ﬂexion of the neck (minimum 45°) [3].
Finally, camptocormia (CC) has been recently fully char-
acterised as a sagittal plane deformity originating either in
the thoracic or lumbar spine appearing during standing or
walking and resolving in the supine position [2].
On the other hand, CC has been incorrectly considered
as a single entity. Nowadays, a consensus has been reached in
diﬀerentiating forward trunk ﬂexion in lower and upper
camptocormias.)e former refers to “an involuntary ﬂexion
of the spine of at least 30° at the lumbar fulcrum (L1-Sa-
crum).” )e latter refers to “an involuntary ﬂexion of the
spine of at least 45° at the thoracic fulcrum (C7 to T12-L1)”
[2]. )is additional classiﬁcation allows the clinician to
deﬁne deformities in the sagittal plane better and then to
investigate whether the diﬀerent types of CC would impose
speciﬁc disability in patients with PD.
So far, only two studies have explored the inﬂuence of
postural abnormalities in gait dynamics and postural control
[8, 9]. Geroin et al. reported for the ﬁrst time that patients
with Pisa syndrome (PS) showed higher (worse) postural
instability than age-matched patients with PD but without
PS and healthy controls (irrespective of side and severity).
Patients with PD and PS reported a signiﬁcantly higher
velocity of the Center of Pressure (CoP) displacement in the
mediolateral and anteroposterior directions than the other
two groups, with the worst performance in the eyes, closed
condition. No signiﬁcant diﬀerences were reported on
spatiotemporal gait parameters among groups [8]. In a
recent observational cross-sectional study, Tramonti et al.
investigated gait dynamics using 3D Gait analysis and
clinical scales in patients with PD and PS, with CC, and
without postural deformities. Gait speed, stride, and step
length decreased in patients without postural abnormalities
and PS and CC groups compared to healthy subjects.
Functional abilities and disease severity were worse in the PS
and CC patients than patients without postural abnormal-
ities. Kinematic data revealed a marked reduction in the
lower-extremity range of motion (ROM) in the patients with
PS. However, the CC group showed a more noticeable re-
duction in hip and knee joints range of motion suggesting an
increased hip ﬂexion pattern during gait [9]. )e main study
limitation is the lack of distinction between upper and lower
CC. )e diagnosis of CC should take into account both the
bending angle and fulcrum to be correctly categorised and
diﬀerentiated from a generically stooped posture [2].
To our knowledge, no studies to date have explored the
relative contribution to gait impairment and postural
control of the upper and lower CC in patients with PD.
Moreover, gait variability and asymmetry have not been
previously investigated in these populations. )e primary
aim of this study was to investigate gait speed diﬀerences in
patients with PD with upper and lower CC and patients with
PD without CC.
)e secondary aim was to investigate changes in the
other spatiotemporal gait parameters according to the
conceptual models of gait [7] between patients with PD with
upper and lower CC and patients with PD without CC. We
hypothesized that patients with lower CC would be more
aﬀected than other groups in both gait and postural control
due to biomechanical constraints to the lumbar/sacral
region.
2. Materials and Methods
2.1. Study Design and Setting. An observational cross-sec-
tional study involving patients with PD with upper CC and
lower CC and without CC (PD) was conducted. Patients
were recruited from the outpatient’s clinic of the Movement
Disorders Division and the UOC Neurorehabilitation Unit
of the University Hospital (AOUI Verona, Italy) fromMarch
2018 to October 2018.
2.2. Participants. Forty-six patients with PD (mean age
70.9± 6.6) were divided into three groups: patients with
upper CC (n � 16), lower CC (n � 14), and without CC
(n � 14). )e severity of forward trunk ﬂexion was evaluated
using a software-based measurement of the undressed (with
underwear) body patients’ pictures. )e lateral view pictures
of the patients were taken with the camera lens at ap-
proximately waist level. )e measurements were performed
by an experienced rater using a freeware program Kinovea®[10].
Patients were diagnosed with CC when presenting an
“involuntary ﬂexion of the spine appearing during standing
or walking and resolving in the supine position of at least 30°
at the lumbar fulcrum (L1-sacrum and hip ﬂexion, i.e., lower
CC) or at least 45° at the thoracic fulcrum (C7 to T12-L1, i.e.,
upper CC)” [2].
At the enrolment, all patients underwent a neurological
screening and physical examination. Inclusion criteria were
age ≥18 years old; clinical diagnosis of PD according to MDS
clinical diagnostic criteria [11]; Hoehn & Yahr (H&Y) stage≤4 in the “ON” medication phase and on their usual anti-
parkinsonian treatment. Exclusion criteria were severe
dyskinesia or “on-oﬀ ” ﬂuctuations; PD medication modi-
ﬁcation in the 3months preceding the enrolment; the
presence of PS [3]; a history of major spinal surgery or
muscle and/or skeletal spine diseases (namely, vertebral
fractures, spondylodiscitis, and inﬂammatory myopathy);
need for assistive devices to rise from a chair or bed; other
neurological (i.e., vertigo and vestibular disorders), ortho-
pedic, or cardiovascular comorbidities that could interfere
with gait; and ability to walk for at least 10meters without
the use of device. Patients gave their written, informed
consent after being informed about the experimental nature
of the study. )e authorization has been obtained for dis-
closure (consent-to-disclose) of any recognizable persons in
photographs. )e study was carried out following the
Helsinki Declaration, approved by the local Ethics Com-
mittee (prog. no. 2399).
2.3. Testing Procedures. Demographic and clinical variables
were collected by an MDS specialist and included age,
gender, Uniﬁed Parkinson’s Disease Rating Scale total score
and Part III (UPDRS III), H&Y stage, PD phenotype (rigid-
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akinetic, tremor-dominant, or mixed type) [12], Montreal
Cognitive Assessment (MOCA) Score [13]; Parkinson’s
Disease Questionnaire-8 Score (PDQ8) [14], the number of
falls in the previous month [15], the Mini-BESTest [16], and
the Numeric Rating Scale (NRS) to quantify back pain.
All patients underwent instrumental gait assessment
using the GAITRite walkway system (CIR Systems Inc,
Havertown, PA) 7.92m in length and sampling at a fre-
quency of 120Hz. )e patients walked at a self-selected
comfortable speed without walking aids. )e data from the
three trials were collected, and their average was calculated.
Gait parameters were selected following a model developed
in older adults and validated in PD composed of ﬁve do-
mains [7, 17]: (1) pace domain: gait speed (cm/s), stride, and
step length (cm), width of base of support (cm), and stride
velocity (cm/sec); (2) rhythm domain: cadence (step/min),
step time (sec), swing time (sec), stance time (sec), single
support time (sec), and double support time (sec); (3)
phases: swing %, stance %, single %, and double support % of
gait cycle; (4) asymmetry domain: step length and stance
time calculated as the absolute diﬀerence between left and
right step means; (5) variability measures were quantiﬁed
using the coeﬃcient of variation, e.g., stride length
variability� 100× (SD of stride length/average stride length)
[18, 19]. )e coeﬃcient of variability for the stride length,
base of the support, double support time, and stride velocity
was computed as related to falling in older adults [20].
Posturography was performed in the standing position
on an electronic monoaxial platform (Technobody©). )e
feet position on the platform was standardized using a
V-shaped frame for all patients. )e distance between the
two malleoli was 3 cm, and the medial borders of the feet
were extra rotated 12° with respect to the anteroposterior
axis. )e patients were evaluated while standing upright
without the use of upper limb support in the eyes open (EO)
and the eyes closed (EC) condition, each lasting 30 s [8]. )e
following outcomes were recorded: the velocity of the CoP
displacement in the anteroposterior and mediolateral di-
rection (mm/sec), length of CoP trajectory (mm), and sway
area (mm2) (Figure 1).
)e primary outcome measure was gait speed while
secondary outcome measures were other spatiotemporal
parameters, gait variability and asymmetry, and stabilo-
metric outcomes.
2.4. Statistical Analysis. Descriptive statistics included cal-
culation of frequency tables, means, and standard deviation.
Absolute and relative frequencies were calculated for cate-
gorical data and tested by Fisher’s Exact test after checking
the minimum acceptable number of expected frequencies
(<5). Variables were tested for normality with the
Shapiro–Wilk test. When the continuous variables were
normally distributed, the comparisons across groups (PD vs
upper CC vs lower CC) were performed with parametric
tests. )e equality of variances (homogeneity) was checked
using Levene’s test. If variances were heterogeneous, we used
Welch’s ANOVA test, otherwise the one-way ANOVA. )e
post hoc comparisons were performed with the Tukey test.
When the continuous variables were not normally distrib-
uted, the comparisons across groups (PD vs upper CC vs
lower CC) were performed with nonparametric Kruskal–
Wallis H test. )e post hoc comparisons were performed
with the Mann–Whitney U test.
Further, Pearson’s or Spearman’s coeﬃcient was used to
analyze the correlations between spatiotemporal gait pa-
rameters (gait speed and stride length), posturographic
parameters (eyes open/close velocity of mediolateral CoP
displacements and length of CoP), and H&Y stage in the
three groups. All tests were bilateral at p< 0.05. Statistical
analysis was carried out using the SPSS for Mac statistical
package, version 20.0.
3. Results
Patients recruited were receiving chronic therapy with a
dopaminergic drug and showed good motor compensation
in appendicular function. None had psychiatric distur-
bances. Patients with upper CC had a forward trunk ﬂexion
of 47.64± 2.66°, and 8 showed a back pain with NRS of
3.2± 1.7. Patients with lower CC had a forward trunk ﬂexion
of 48.24± 13.85°, and 9 showed a back pain with NRS of
4.7± 2.2. Patients without CC had a forward trunk ﬂexion of
19.12± 20.25°, and 8 showed a back pain with NRS of
3.1± 1.4.
We found a main eﬀect for the H&Y (F� 5.04; df� 2,
p � 0.011), PDQ8 (p � 0.043), and the Mini-BESTest
(F� 5.55; df� 2, p � 0.007) (Table 1). Post hoc analysis
revealed a signiﬁcant diﬀerence between PD and patients
with lower CC in the H&Y stage (p � 0.003), PDQ8
(p � 0.042), and Mini-BESTest (p � 0.006).
3.1. Primary OutcomeMeasures. A signiﬁcant main eﬀect in
the gait speed (F� 5.37; df� 2, p � 0.011) was measured.
Post hoc analysis revealed that patients with lower CC had a
signiﬁcantly reduced gait speed than patients with PD
(p � 0.012).
3.2. Secondary Outcome Measures. A signiﬁcant main eﬀect
in the stride length (p< 0.001), step length (p< 0.001), and
stride velocity (F� 5.39; df� 2, p � 0.011) was reported. Post
hoc analysis revealed a signiﬁcant diﬀerence in stride length
between PD and patients with lower CC (p< 0.001) and
between patients with lower CC and upper CC (p � 0.007).
In step length, a signiﬁcant diﬀerence between PD and
patients with lower CC (p< 0.001) and between patients
with lower CC and upper CC (p � 0.008) was measured.
Patients with lower CC showed a signiﬁcant shorter stride
and step length than patients with PD and upper CC. In
stride velocity, post hoc analysis revealed a signiﬁcant dif-
ference between PD and patients with lower CC (p � 0.012).
Post hoc analysis revealed that patients with lower CC had a
signiﬁcant slower stride velocity than patients with PD. No
statistically signiﬁcant results were reported in the other
spatiotemporal gait parameters.
In the eyes open condition, a signiﬁcant main eﬀect in
the velocity of CoP in the mediolateral direction (p � 0.004)
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and length of CoP (p � 0.019) was reported. Post hoc
analysis revealed a signiﬁcant diﬀerence between PD and
patients with lower CC in the velocity of CoP (p � 0.003)
and the length of CoP (p � 0.014).
Similarly, a signiﬁcant main eﬀect in the velocity of CoP
in mediolateral direction (p � 0.011) and length of CoP
(p � 0.015) was measured in the eyes closed condition. Post
hoc analysis revealed a signiﬁcant diﬀerence between PD
and patients with lower CC in the velocity of CoP
(p � 0.009) and the length of CoP (p � 0.014).
In eyes open and closed condition, patients with lower
CC revealed a higher velocity of CoP in mediolateral
direction and length of CoP than patients with PD. We did
not ﬁnd any other statistically signiﬁcant results.
No signiﬁcant correlation coeﬃcients were found be-
tween spatiotemporal gait parameters (gait speed and stride
length), posturographic parameters (eyes open/closed ve-
locity of mediolateral CoP displacements and length of
CoP), and H&Y stage in the three groups.
4. Discussion
)e main ﬁnding of this study is that the patient with lower
CC exhibited the highest degree of gait and postural control
(a) (b) (c)
Figure 1: A patient with lower CC during the gait (a) and posturographic assessment with eyes open (b) and eyes closed condition (c).
Table 1: Demographic and clinical characteristics of the patients.
Total Group CC Upper CC Lower PD p Value
Patients, no. 46 16 14 16
Age, mean (SD), yrs 70.9 (6.6) 71.6 (4.36) 70.3 (8.21) 70.7 (7.3) 0.787c
Gender, M/F 31/15 12/4 7/7 12/4 0.283
UPDRS total score 53.1 (23.9) 53 (30.2) 59.6 (18.4) 47.5 (21.1) 0.250c
UPDRS III score 29.7 (14.3) 29.2 (17.6) 33.9 (11.9) 26.4 (12.2) 0.283c
H&Y stage 2.2 (0.8) 2.2 (0.9) 2.6 (0.6) 1.8 (0.6) 0.011∗a
Dominant phenotype, n (%) 0.131c
Tremor type 11 (24) 5 (31.2) 1 (7.2) 5 (31.2) —
Bradykinetic/rigid type 29 (63) 7 (43.8) 12 (85.7) 10 (62.5) —
Mixed type 6 (13) 4 (25) 1 (7.1) 1 (6.3) —
MoCA 24.3 (3.3) 23.7 (3.9) 24.1 (3.1) 25.2 (3.1) 0.545c
PDQ8 20.1 (13.3) 18.2 (11.8) 25.9 (13.1) 16.8 (14) 0.043∗ac
Falls 1.1 (1.9) 1.2 (2.5) 1.6 (1.8) 0.5 (0.9) 0.175c
Mini-BESTest 19.6 (5.6) 19.1 (6.5) 16.6 (4.7) 22.7 (3.6) 0.007∗a
CC denotes patients with Parkinson’s disease and camptocormia according to consensus-based diagnostic criteria (Fasano2018); PD, patients with Par-
kinson’s disease (without CC); SD, standard deviation; M, Male; F, Female; yrs, years; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale; UPDRS III, subitem
of UPDRS scale part III; H&Y, Hoehn and Yahr stage; MoCA,Montreal Cognitive Assessment; PDQ8, Parkinson’ s Disease Questionnaire-8; Falls, number of
falls in the previous month; aWelch’s ANOVA test; bFisher’s exact test; cKruskal–Wallis H test; p signiﬁcant if< .05; values with ∗ and in bold are considered
statistically signiﬁcant.
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impairment. Our data extend previous data on the inﬂuence
of CC on functional performance during walking and, for
the ﬁrst time in the literature, showed that the two types of
CC may aﬀect (or not) gait and postural control [2, 9].
According to the literature [2, 3], the presence of CC was
associated with higher neurological severity, worse balance
performance, and quality of life than patients without CC, as
reported in Table 1. However, only patients with lower CC
reported scores signiﬁcantly worse than patients without
CC. Gait analysis and postural assessment showed that lower
CC was associated with a signiﬁcant reduction in perfor-
mance in the pace domain (except for the width of the base
of support). Besides, a signiﬁcant increase in the velocity of
the CoP displacement in mediolateral direction and length
of CoP in both eyes open and closed conditions was re-
ported. )is ﬁnding was signiﬁcantly diﬀerent between
upper and lower CC strengthening, the hypothesis that
lower CC aﬀects gait more than the upper type. )us, the
forward trunk ﬂexion by lower fulcra may be the most
disabling postural abnormalities in patients with PD.
Table 2: Multiple pairwise comparisons between the three groups for each outcome measure.
Spatiotemporal gait parameters CC Upper CC Lower PD p Valuemain eﬀect
Pace domain
Gait speed (cm/s) 96.27 (16.62) 79.05 (20.74) 108.55 (30.90) 0.011∗
Stride length (cm) 106.27 (15.36) 83.61 (4.74) 115.26 (21.93) <0.001∗
Step length (cm) 53 (7.69) 41.67 (8.81) 57.42 (10.95) <0.001∗
Width of base support (cm) 8.77 (3.04) 9.71 (3.91) 8.95 (3.07) 0.725
Stride velocity (cm/s) 97.05 (16.55) 79.81 (20.91) 109.66 (31.05) 0.011∗
Rhythm domain
Cadence (step/min) 109.04 (10.89) 113.10 (15) 111.94 (13.23) 0.679
Step time (sec) 0.55 (0.06) 0.54 (0.07) 0.54 (0.06) 0.723
Swing time (sec) 0.42 (0.04) 0.38 (0.04) 0.40 (0.03) 0.149
Stance time (sec) 0.69 (0.07) 0.68 (0.11) 0.68 (0.09) 0.924
Single support time (sec) 0.42 (0.04) 0.38 (0.04) 0.40 (0.03) 0.149
Double support time (sec) 0.28 (0.04) 0.30 (0.10) 0.28 (0.08) 0.966
Phases
Swing % of gait cycle (%) 37.48 (1.43) 36.26 (3.22) 37.31 (2.62) 0.673
Stance % of gait cycle (%) 62.52 (1.44) 63.73 (3.22) 62.70 (2.62) 0.687
Single support % of cycle 37.49 (1.41) 36.25 (3.23) 37.32 (2.61) 0.643
Double support % of cycle 25.07 (2.87) 27.35 (6.51) 25.36 (5.12) 0.704
Asymmetry
Step length diﬀerence (cm) 4.12 (2.65) 2.97 (2.11) 2.36 (1.51) 0.072
Stance time diﬀerence (sec) 0.01 (0.03) 0 0 0.365
Coeﬃcient of variability
Stride length, CV 5.18 (1.96) 5.83 (2.62) 4.77 (2.11) 0.479
HH base support, CV 22.88 (12.79) 22.97 (13.33) 24.06 (11.11) 0.957
Double support time, CV 14.81 (11.08) 13.24 (7.06) 13.65 (7.92) 0.995
Stride velocity, CV 7.74 (2.89) 9.24 (4.29) 7.78 (2.95) 0.674
CC denotes patients with Parkinson’s disease and camptocormia according to consensus-based diagnostic criteria [2]; PD, patients with Parkinson’s disease
(without CC); p signiﬁcant if <0.05; values with ∗ and in bold are considered statistically signiﬁcant.
Table 3: Multiple pairwise comparisons between the three groups for each posturography measure.
Posturography CC Upper CC Lower PD p Valuemain eﬀect
Variables eyes open
VEL_MED_AP (mm/sec) 4.25 (2.08) 5.78 (3.55) 3.56 (1.31) 0.086
VEL_MED_ML (mm/sec) 3.25 (1.34) 4.57 (2.03) 2.56 (1.09) 0.004∗
Length CoP (mm) 149.12 (62.92) 206.50 (106.65) 121.18 (43.90) 0.019∗
Sway area (mm2) 93.62 (108.71) 125.14 (110.33) 79.56 (61.72) 0.518
Variables eyes closed
VEL_MED_AP (mm/sec) 6.18 (2.76) 7.78 (5.21) 4.37 (1.63) 0.050
VEL_MED_ML (mm/sec) 4.56 (1.78) 6.28 (3.45) 3.37 (1.74) 0.011∗
Length CoP (mm) 215.50 (86.26) 282.21 (163.26) 157.25 (59.65) 0.015∗
Sway area (mm2) 168.44 (171.36) 181.86 (122.67) 113 (125.57) 0.069
CC denotes patients with Parkinson’s disease and camptocormia according to consensus-based diagnostic criteria [2]; PD, patients with Parkinson’s disease
(without CC); CoP, centre of pressure; VEL_MED_AP, velocity of anteroposterior CoP displacement; VEL_MED_ML, velocity of mediolateral CoP
displacement; p value, Kruskal–Wallis test; P signiﬁcant if <0.05; values with ∗ and in bold are considered statistically signiﬁcant.
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CC is not a levodopa-responsive abnormality that can be
(before being more ﬁxed) fully reversible in the supine
position and using manoeuvres like “sensory tricks” (i.e., the
patients to stand up straight or against a vertical reference)
[4]. )e existing evidence suggests that CC may have
multifactorial pathophysiology involving central and pe-
ripheral hypotheses [3, 4]. )e former, supported by animal
and clinical studies, takes into account an asymmetric
functioning of basal ganglia output leading to asymmetric
control of trunk muscles tone (dystonia) along with an
altered internal model of postural perception [4]. )e latter
considers CC as a consequence of paraspinal myopathy due
to the pathophysiology of PD. However, this possibility
needs to be further investigated [4]. Distinct muscles pat-
terns might be involved in the bimodal distribution of
forward trunk ﬂexion. In the upper CC, a bilateral over-
activity of abdominal external and internal oblique along
with rectus abdominis muscles has been described
[4, 21–23].
In contrast, in the lower subtype, combined activation of
rectus abdominis and iliopsoas muscles has been reported
[4]. Our ﬁnding suggested two mutually nonexclusive hy-
potheses. From a biomechanical perspective, the lower CC
may compromise the iliopsoas function. As reported by the
physiological literature, the iliopsoas muscle ﬂexes the femur
in the standing position and acts as a stabilizer of the femoral
head in the hip acetabulum in the ﬁrst 15° of movements.
Finally, it maintains the director action from 15° to 45°
degrees and acts as an eﬀective ﬂexor of the femur from 45 to
60° [24]. )e reduced stride length and gait speed found in
patients with lower CC might be explained by the patho-
logical ﬂexion of the trunk during gait limiting the hip
extension. )e reduction of hip extension, indeed, is a
primary factor in the reduction of the ROM at the hip, step
length, and gait speed [5, 9]. Moreover, the excessive ﬂexor
muscle activity at the knee and ankle further reduced lower
limb joint torques during walking [6].
From a neurological perspective, gait slowness may be
the result of more severe hypokinesia (reduced step size),
bradykinesia (increased step duration), and axial rigidity.
It would explain why patients with lower CC displayed a
severe neurological severity, as measured by the H&Y
stage.
Walking can be understood as a repeated sequence of the
centre of mass displacements tomaintain lateral and forward
stability [6]. A decrease of gait speed is a self-imposed
compensatory strategy to maintain balance during walking
in PD.)e low gait speed observed in patients with lower CC
can be related to a worsening of balance control, as measured
by the mediolateral CoP displacement. )e abnormal ﬂexed
posture observed in lower CC pushes the CoP forward the
base of support at the limits of stability. )e literature
emphasised that the lateral control of balance is impaired in
patients with PD showing elevated lateral trunk sway during
stance and walking [5] and it is associated with falls [6].
Patients with lower CC might be less prone to sway in the
anteroposterior direction than in the mediolateral direction
because of the hyperﬂexed posture limiting the hip range of
motion in the anteroposterior direction. As a consequence,
the patient with lower CC reported a higher number of falls
than the other two groups, albeit not signiﬁcant.
)e three groups were comparable in gait variability and
asymmetry, suggesting that these domains might be in-
dependent of the CC and related to the disease severity itself
[6]. According to the literature, our results suggest that gait
variability is independent of gait speed, cadence, and stride
length [25]. An increase in gait variability in PD is expected
in comparison with healthy controls presumably related to
basal ganglia dysfunction and not to CC [25, 26]. Gait speed
and stride length parameters showed in our PD patients
were similar to ﬁndings reported in older adults [27]. It
suggests that the stage of disease and phenotype have a
primary role in impairing gait and balance in PD.
)e main study limitation is the lack of 3D gait analysis
to assess trunk and lower limbs during gait quantitatively.
Larger sample size may strengthen the statistics of the study
and display signiﬁcant diﬀerences among groups not found
in our preliminary report.
5. Conclusions
Lower CC was associated with more severe gait and postural
control impairment than upper CC and without CC. Cat-
egorizing CC based on the bending fulcrum is compulsory to
identify patients with the worst outcome and to implement
speciﬁc rehabilitation programs. Future rehabilitation
studies are needed to assess the rehabilitation eﬀects on the
severity of the forward trunk ﬂexion and postural control in
patients with lower camptocormia (Tables 2 and 3).
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